Clinical trial · Observational
DNA Repair and Genetic Susceptibility to Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to help us better understand the cellular changes that may lead to the development of lung cancer. We want to compare people with a second primary lung cancer with those who have only a first primary lung cancer. We hope to use the information obtained in this study as the basis for future studies and will not regard the results from this study as final. We will analyze your blood cells and DNA to measure the changes in several genes that we believe may be involved in lung cancer. We also want to evaluate the capacity for your DNA to repair itself.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Second Primary Lung Cancer | — | UNRESOLVED | — |
| Single Primary Lung Cancer | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Blood draw and Questionnaires | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- 1
- description
- second primary lung cancer
- interventionNames
- Other: Blood draw and Questionnaires
- label
- 2
- description
- single primary lung cancer
- interventionNames
- Other: Blood draw and Questionnaires
Primary outcomes (1)
- measure
- To conduct a pilot study of the role of DNA repair in lung cancer subjects with high genetic risk - those with a second primary lung cancer - compared to subjects with only one lung cancer.
- timeFrame
- conclusion of the study
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Cases will be eligible for inclusion if: * They have been diagnosed with a second primary lung cancer, and * They speak English or a language for which we have a translated consent form, and * They understand and agree to sign informed consent, and * They agree to give us a blood sample, and * They agree to give us a tissue sample when part of normal clinical procedures, and * They agree to complete the study questionnaires, and * They agree to have their pathology information reviewed. This could include biopsy specimens. Controls will be eligible for inclusion if * They have been diagnosed with a first primary lung cancer, and * They speak English or a language for which we have a translated consent form, and * They understand and agree to sign informed consent, and * They agree to give us a blood sample, and * They agree to give us a tissue sample when part of normal clinical procedures, and * They agree to complete the study questionnaires, * They agree to have their pathology information reviewed. This will could include biopsy specimens. Exclusion Criteria: * Subjects who do not meet the inclusion criteria as either cases or controls will not be eligible for this study. * Control subjects who have a history of another cancer, other than nonmelanoma skin cancer or a first primary lung cancer, will not be eligible for this study. * Control subjects who otherwise meet the eligibility requirements above but who have had chemotherapy and/or are currently being treated with chemotherapy will be excluded from the functional assay, but not from the genotyping.
References
Publications (0)
Data not yet available